Agilent, Ambion Announce Co-Marketing Deal | GenomeWeb

NEW YORK, Aug 10 - Agilent Technologies and Ambion have agreed to co-market several of their products, including the Agilent 2100 bioanalyzer, Agilent RNA LabChip kits, and Ambion's RNA-related reagents. 

The companies said that by combining forces, they would be able to offer customers a range of products for improved RNA analysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.